Everstone Capital, a Pan Asia private equity fund, is merging Translumina Therapeutics, a major cardiac stent maker in India, as part of a ...

Existing investor Samara Capital and the promoter, Dhirajlal Kotadia and his family, are also likely to sell an about 15-20% stake between ...

Avanse is the second largest domestic private sector NBFC in the education loan segment with assets under management (AUM) of Rs 8,646 cror...

The Rs 2,000-crore Kotak fund, an India-focused late-stage alternative investment fund (AIF), primarily focuses on investments in late-stag...

Established in 1998, SMT develops and manufactures cardiac products that are sold in 75 countries. Its portfolio includes coronary stents (...

The reduction in stent prices enthused Indian manufacturers, which had been on the fringes of the business and had been desperately trying ...

The decision is a blow for stent makers, who have been clamouring for higher prices and a system to rationalise margins instead of blanket ...

As multinational stent makers ponder their prospects in India after price controls introduced this year, their local rivals have popped up ...

Emilia Romagna is one of the most populous regions of north Italy, with 15 cath labs performing 10% of Italian Percutaneous Coronary Interv...

This year, domestic stent firms are aiming for 60 per cent of the market estimated to be Rs 1,200 crore now due to a drop in the average pr...

Following the NPPA decision, some companies have reportedly withdrawn high-priced stents, leading to an artificial shortage of the product.

A cardiologist who spoke to ET on condition of anonymity said some companies, especially importers, have asked hospitals not to use stents ...

As part of the deal, Samara Capital's managing director Gautam Gode and vice president Abhishek Kabra will come on SMT's board.

The company will test the quality, safety and efficacy of 86 variations of Supraflex stents against their Xience equivalents between now an...